Drug intelligence / Profile preview

Rubiven

Development stage: Unknown
Lead developer: Meroven
Modality: Small Molecules
Administration: Topical

Overview

**Rubiven** is a Meroven topical analgesic cream for relief of musculoskeletal and rheumatological pain. It contains methyl salicylate, menthol, eucalyptus oil, and turpentine oil. The formulation produces topical counterirritant and analgesic effects, including cooling and warming skin sensations that help alleviate localized muscle and joint discomfort. It is applied externally to intact skin. ([meroven.com](https://www.meroven.com/rheumatology.html))

Brand names: Rubiven

Beyond the preview

Go deeper on Rubiven.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Rubiven.

Explore the full profile